Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping Categories

  1. 1. Mobile Phones
  2. 2. Digital Cameras
  3. 3. Smartphones
  4. 4. Laptop Computers
  5. 5. Graphics Cards
  6. 6. Fridges
  7. 7. LCD TVs
  8. 8. LCD Monitors
  9. 9. Vacuum Cleaners
  10. 10. Freezers
  11. 11. Washing Machines
  12. 12. Microwaves
  13. 13. Electric Kettles
  14. 14. Dishwashers
  15. 15. Digital Camcorders

Wikio Shopping

  1. 1. Baby & Nursery
  2. 2. Books
  3. 3. Car/Motorbike
  4. 4. CD
  5. 5. Communication
  6. 6. Computers
  7. 7. DVD
  8. 8. Electronics
  9. 9. Entertainment
  10. 10. Fashion & Lingerie
  11. 11. Finance
  12. 12. Gifts & Gadgets
  13. 13. Health & Beauty
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Sport & Fitness
  18. 18. Travel
  19. 19. Video Games

Participate



Sanofi-Aventis



Sort by : relevance - date - popularity
3Vote!

Emisphere Technologies Appoints Tim Rothwell to the Board of Directors

CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company’s Board of Directors effective immediately. Mr. Rothwell’s appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business...

3Vote!

Sanofi Aventis (SNY) Trading In Tight Support/Resistance Range

Sanofi Aventis (NYSE: SNY) closed yesterday at $36.99. So far the stock has hit a 52-week low of $23.95 and 52-week high of $40.17. Sanofi Aventis stock has been showing support around 36.38 and resistance in the 37.66 range. Technical indicators for the stock are Neutral and S&P gives SNY a neutral 3 STAR (out of 5) hold rating. SNY appears on the Investors Observer Analysts Favorites list. For...

3Vote!

Aureus Pharma Extends Its Knowledge Database Agreement with Sanofi-Aventis R&D

PARIS--(BUSINESS WIRE)--Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term. Under the agreement, Aureus will provide new AurSCOPE® knowledge databases and continue to update existing...

3Vote!

A 130 / 30 Global Pharma Strategy

Mike Havrilla submits: Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent...

3Vote!

India approaches WTO as yet another seizure takes place

Even as India and other developing countries are on the verge of filing a formal complaint at the WTO with regard to the 17 highly controversial seizures which have occurred since late last year (which we have posted several times on here ) yet another consignment of drugs has been seized last month on grounds of patent violation, this time in France. The consignment was of 1.74 million pills of the...

3Vote!

[khabor.com] Bangladesh a “huge opportunity” for growth; CEO

Shortcut to: http://www.outsourcing-pharma.com/On-your-radar/Globalisation/Bangladesh-a-huge-opportunity-for-growth-CEO Bangladesh a "huge opportunity" for growth; CEO By Nick Taylor, 09-Sep-2009 Related topics: Globalisation , Contract Manufacturing , Bulk ingredients , Drug delivery, formulation , Fill & finish, packaging , Validation services Bangladesh represents a " huge opportunity...

3Vote!

CombinatoRx Reports Financial Results for the Third Quarter 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today reported financial results for the third quarter ended September 30, 2009. “With a number of recent positive product-related updates, including an FDA Advisory Committee on Exalgo and its REMS program, Sanofi-Aventis’ acquisition of Prednisporin, a CombinatoRx-derived combination drug candidate, through its...

3Vote!

FTC, Canada Competition Bureau Approve Schering-Plough’s Acquisition...

FTC, Canada Competition Bureau Approve Schering-Plough’s Acquisition of Merck This posting was written by Jeffrey May, Editor of CCH Trade Regulation Reporter. Schering-Plough Corporation can proceed with its proposed $41.1 billion acquisition of Merck & Co. Inc. under the terms of a proposed FTC consent order, according to the agency's October 29 announcement . The consent order would settle...

3Vote!

Prasco, Winthrop ink distribution deal

Prasco Laboratories said Monday it has signed sales and distribution agreements with Winthrop U.S., a unit of Sanofi-Aventis U.S. (SNY)

3Vote!

Intense Pharmaceutical Lobbying Prompts Inquiry

A lobbying war between two pharmaceutical companies vying to market a generic blood-thinner has prompted an inquiry by Sen. Chuck Grassley and Senate Finance Committee Chairman Max Baucus, reports the Wall Street Journal. Drug makers Amphastar Pharmaceuticals Inc. and Momenta Pharmaceuticals Inc. both applied to the Food and Drug Administration several years ago to make a generic version of the blood-thinning...

3Vote!

Court Rejects Drug-Patent Challenge

The Supreme Court Monday rejected a generic-drug maker's appeal challenging a patent for a blood-thinning drug developed by Sanofi-Aventis.

3Vote!

Sanofi-Aventis Names Spek Global Operations Head

Sanofi-Aventis names pharma business head Hanspeter Spek as president of global operations

3Vote!

Sanofi-Aventis names Spek global operations head

French drugmaker Sanofi-Aventis says it is promoting two high-ranking executives and adding a third to its executive committee.

5Vote!

High costs of malaria drug cause millions of deaths

The cost of the anti-malaria drug Artemisinin combination therapy is more than poor people can afford. Researchers are saying that the high cost results in another million deaths a year from malaria. Poor malaria sufferers instead go to an an older, cheaper drug that is not nearly as effective as ACT. From Reuters, reporter Kate Kelland tells us more about the study into malaria drug use. Artemisinin...

3Vote!

Shook Hardy's Asleep At The Wheel

We have rules at this blog: We don't criticize drug and device companies, and we don't criticize defense law firms. But we're making an exception here, and we bet you can understand why: Shook Hardy won an interesting case last week involving the sleeping pill Ambien. More than a dozen folks from Shook Hardy subscribe to this blog. Yet none of those subscribers told us about the firm's victory! We...